	US 11,951,092 B2
	Agent for preventing or treating brain atrophy
Hiroshi Kobayashi, Tokyo (JP); and Yoshihiko Matsumoto, Tokyo (JP)
Assigned to FUJIFILM Toyama Chemical Co., Ltd., Tokyo (JP)
Appl. No. 16/617,739
Filed by FUJIFILM Toyama Chemical Co., Ltd., Tokyo (JP)
PCT Filed Jun. 1, 2018, PCT No. PCT/JP2018/021223 § 371(c)(1), (2) Date Nov. 27, 2019, PCT Pub. No. WO2018/221729, PCT Pub. Date Dec. 6, 2018.
Claims priority of application No. JP2017-109885 (JP), filed on Jun. 2, 2017; application No. JP2017-128472 (JP), filed on Jun. 30, 2017; and application No. JP2017-145100 (JP), filed on Jul. 27, 2017.
Prior Publication US 2020/0215030 A1, Jul. 9, 2020
This patent is subject to a terminal disclaimer.
Int. Cl. A61K 31/397 (2006.01); A61K 9/00 (2006.01); A61P 25/28 (2006.01)

CPC A61K 31/397 (2013.01) [A61K 9/0053 (2013.01); A61P 25/28 (2018.01)]

8 Claims

1. A method of preventing or treating brain atrophy in humans, comprising administering 1-(3-(2-(1-benzothiophen-5-yl)ethoxy)propyl)azetidin-3-ol or a salt thereof to a human patient.